Definitive Healthcare Corp.
No SEC Form 4 filings for $DH in the last 30 days.
See all $DH insider activity →Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.
Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dh-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Hea
Definitive Healthcare Corp. has reached a new 52-week low of $1.37, marking a significant 76.41% drop in its stock price over the past year. With a market capitalization of $214 million and a P/E ratio of 6.00, the company exhibits limited profitability and has underperformed the S&P 500. This decline reflects ongoing competitive challenges in the Software Products industry.
Over the past 7 days, alphai's AI scored 1 news story mentioning DH (Definitive Healthcare Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent DH coverage spans financial news and earnings.
Guidance raise plus improving retention and margin, but life sciences softness and weaker professional services bookings keep downside risk.
The filing provides fresh earnings and forward guidance, plus profitability and cash flow metrics, which can drive near-term estimate and positioning changes.
Definitive Healthcare Corp. (DH) has experienced a significant decline, reaching a new 52-week low at $1.37, with a 76.41% drop over the past year. The company's weak profitability metrics and underperformance relative to the S&P 500 suggest ongoing challenges.
The expansion of claims data by Definitive Healthcare (DH) suggests potential positive implications for the company's revenue streams and market positioning within healthcare analytics.
Definitive Healthcare (DH) reported a strong Q3 earnings and revenue beat, with earnings surpassing estimates by 16.67% and revenue by 1.04%. This positive surprise indicates potential upward momentum.
alphai scores every news story that mentions DH with an AI model for sentiment and relevance, and aggregates insider trades from Definitive Healthcare Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.
6 min readDefinitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dh-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Hea
6 min readDefinitive Healthcare Corp. has reached a new 52-week low of $1.37, marking a significant 76.41% drop in its stock price over the past year. With a market capitalization of $214 million and a P/E ratio of 6.00, the company exhibits limited profitability and has underperformed the S&P 500. This decline reflects ongoing competitive challenges in the Software Products industry.
4 min readDefinitive Healthcare announced a significant expansion of its prescription and all-payor medical claims data within the Atlas Dataset, increasing coverage by over 60% for prescription claims and considerably for all-payor claims, including a nearly 20% rise in key areas like rare disease and oncology. This expansion, coupled with refined methodologies and increased patient overlap, provides clients with a more in-depth and holistic view of patient journeys to better understand market trends, inform product development, and optimize go-to-market strategies. The enhanced data aims to accelerate commercial success for organizations partnering with healthcare providers.
2 min readDefinitive Healthcare (DH) delivered earnings and revenue surprises of +16.67% and +1.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readDefinitive Healthcare (DH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min readDH vs. BL: Which Stock Is the Better Value Option?
3 min readDefinitive Healthcare (DH) delivered earnings and revenue surprises of +40.00% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readU.S. stocks traded lower midway through trading, with the Dow Jones index falling around 0.5% on Friday. The Dow traded down 0.46% to 41,180.09 while the NASDAQ fell 0.19% to 17,894.56. The S&P 500 also fell, dropping, 0.20% to 5,652.60. Consumer discretionary shares rose by 1% on Friday.
3 min readU.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 0.5% on Friday. Following the market opening Friday, the Dow traded up 0.11% to 41,415.78 while the NASDAQ gained 0.50% to 18,018.26. The S&P 500 also rose, gaining, 0.27% to 5,679.25.
3 min read
